3,164 articles
Samsung’s reported interest in acquiring Blackberry highlights the value of Blackberry’s patent portfolio and strategic assets. The potential deal faces regulatory scrutiny in Canada and could impact competition…
Online piracy, particularly of movies, was a key topic during the India-US CEO Forum, reflecting its impact on the entertainment industry. Leaders from both countries recognised the urgent…
Xiaomi’s patent dispute in India with Ericsson led to a temporary sales ban, but Qualcomm-powered devices can still be sold. The company assures that ongoing legal challenges will…
This presentation by Dr. Kalyan C. Kankanala was delivered at Bosch, India on Data Privacy Day, January 28, 2015. It examines the evolution of the right to privacy…
Gilead’s patent for Sofosbuvir was rejected by the Indian Patent Office on grounds of insufficient therapeutic efficacy. This landmark decision enables wider access to affordable generic Hepatitis C…
On the occasion of International Data Privacy Day on 28/01/2015, Bosch, the global engineering and electronics major, invited Dr. Kalyan to deliver a lecture on privacy and its…
Bar & Bench interviewed Dr. Kalyan C. Kankanala on 26/01/2015 about his legal thriller “Pirates of Bollywood”, an IP-themed novel aimed at making intellectual property concepts accessible to…
This excerpt from Pirates of Bollywood presents a legal debate on copyright infringement involving technology platforms and indirect liability. The counsels discuss the balance between creative freedom and…
The Indian Patent Office has revoked Roche’s patent on Bonviva after Cipla challenged its validity, citing a lack of inventive step and patentability. This decision highlights critical aspects…
Weekly IP Warm-UP covers notable intellectual property law updates, including copyright and patent litigation, music industry developments, and trade secrets cases. The post analyses recent legal changes and…
The Charlie Hebdo attack in Paris in January 2015 left a lasting impact on the creative community, bringing attention to the risks faced by those championing free expression.…
The Indian Patent Office set aside Abbott Biotechnology's Humira patent after Glenmark's pre-grant opposition, citing lack of inventive step and insufficient disclosure. This legal dispute underscores ongoing challenges…